Again we are still at very early stages in human trials, but this is why I think we may be on something really special..
The above is data that people are getting excited about for gliomas … remembering we got a 75% disease control rate in our low dose, which was only administered directly to the tumour site. We are going to go dual route from cohort 2 onwards and ramp up the dosages…
so compare our results so far vs the best of the rest…
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |